Artificial liver support: Quo Vadis?

Annals of Transplantation

Volumn 15, Issue 4, 2010, Pages 92-101

  Rozga, Jacek ^a   Malkowski, Piotr ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Albumin; Artificial liver support; Blood purification; Detoxification; Liver failure

Indexed keywords

ACUTE LIVER FAILURE; ARTICLE; BIOARTIFICIAL LIVER; CHRONIC LIVER FAILURE; GRAFT SURVIVAL; HEMOFILTRATION; HUMAN; LIVER SUPPORT; LIVER TRANSPLANTATION; PLASMAPHERESIS; TOXEMIA;

HUMANS; LIVER FAILURE; LIVER, ARTIFICIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78651236626     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Merrill JP, Smith S III, Callahan EJ III: The use of an artificial kidney: II. Clinical experience. J Clin Invest, 1950; 29: 425-438
2. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C: Artificial and Bioartificial Support Systems for Acute and Acute-on-Chronic Liver Failure. A Systemiatic Review. JAMA, 2003; 289: 217-222
3. van de Kerkhove MP, Hoekstra R, Chamuleau RFM, van Gulik TM: Clinical Application of Bioartificial Liver Support Systems. Ann Surg, 2004; 240: 216-230
4. Rozga J: Liver support technology - an update. Xenotransplantation, 2006; 13: 380-389
5. Banares R, Nevens F, Larsen FS et al: Extracorporeal liver support with the molecular adsorbent recirculating system (MARS®) in patients with acuteon- chronic liver failure (ALOF). 11th International Symposium on Albumin Dialysis in Liver Disease, Rostock, May 14th-16th, 2010; 8-9, Abstract book
6. Rifai K, Kribben A, Gerken G et al: A Prospective Randomized Controlled Multicenter Study of Extracorporeal Liver Support by Fractionated Plasma Separation and Absorption (Prometheus®) in Patients with Acute-On-Chronic Liver Failure (HELIOS Study). Hepatology, 2010; 52(Suppl.): 333A
7. Larsen FL, Schmidt LE, Wendon J et al: Liver Assisting with High-Volume Plasma Exchange in Patients with Acute Liver Failure. Hepatology, 2010; 52(Suppl.): 376A
8. Centers for Disease Control and Prevention - National Center for Infectious Diseases. Data available at www.cdc.gov/ncidod/diseases/hepatitis
9. Dietreich D: Strategies for the management of HCV/HIV coinfection. In: Hepatitis C. Disease. Management Guide, 3®d Edition; PDR 2005; 101-113
10. Asrani SK, Kamath PS, Pedersen R et al: Liver related mortality in the US is underestimated. Hepatology 2010; 52 (suppl): 408A.
11. Centers for Disease Control, US National Vital Statistics Report, 2003; 52(9): Table D, page 8
12. Davis GL, Albright JE, Cook SF et al: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl, 2003; 9: 331-338
13. Schiodt FV, Atillasoy E, Shakil AO et al: Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transplant Surg, 1999; 5: 86-89
14. Trey C, Davidson C: The management of fulminant hepatic failure. Progr Liver Dis, 1970; 3: 282-298
15. Bernuau J, Rueff B, Benhamou J-P: Fulminant and subfulminant liver failure: Definitions and causes. Semin Liver Dis, 1986; 6: 97-106
16. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 1977; 349: 825-832
17. Ascher NL, Lake JR, Emond JC, Roberts JP: Liver transplantation for fulminant hepatic failure. Arch Surg, 1993; 128: 677-682
18. Lee WM: Acute liver failure. N Engl J Med., 1993; 329: 1862-1872
19. Farges O, Kalill N, Samuel D et al: The use of ABOincompatible grafts in liver transplantation; a lifesaving procedure in highly selected patients. Transplantation, 1995; 59: 1124-1133
20. Evenepoel P, Laleman W, Wilmer A et al: Detoxifying Capacity and Kinetics of Prometheus® - A New Extracorporeal Systems for the Treatment of Liver Failure. Blood Purif, 2005; 23: 349-358
21. Hassanein TI, Toften F, Brown RS Jr et al: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology, 2007; 46: 1853-1862
22. Saliba F, Camus C, Durand F et al: Randomized controlled multicenter trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant and subfulminant hepatic failure. Hepatology, 2008; 48(Suppl.): 377A
23. Hessel FP: Economic evaluation of the artificial liver support system MARS in patients with acuteon-chronic liver failure. Bio Med Central. Cost Effectiveness and Resource Allocation 2006, 4: 16. Available online at www.resource-allocation.com/content/4/1/16
24. Available at http://en.wikipedia.org/wiki/Liver_dialysis
25. Hui T, Rozga J, Demetriou AA: Bioartificial liver support. J Hepatobiliary Pancreat Surg, 2001; 8: 1-15
26. Rozga J, Williams F, Ro M-S et al: Development of a Bioartificial Liver: Properties and function of a hollow-fiber module inoculated with liver cells. Hepatology, 1993; 17: 258-265
27. Watanabe F, Mullon C J-P, Hewitt WR et al: Clinical Experience with a Bioartificial Liver (BAL) in the Treatment of Severe Liver Failure: A Phase I Clinical Trial. Ann Surg, 1997; 5: 484-494
28. Demetriou AA, Brown AS, Busuttil RW et al: Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Hepatic Failure. Ann Surg, 2004; 239: 660-670
29. Sussman NL, Chong MG, Koussayir T et al: Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology, 1992; 16: 60-65
30. Mavri-Damelin D, Damelin LH, Eaton S et al: Cells for bioartificial liver devices: The human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng, 2008; 99: 644-651
31. Nyberg SL, Remmel RP, Mann HJ: Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functios in bioartificial liver. Ann Surg, 1994; 220: 59-67
32. Denner J: Porcine Endogenous Retroviruses (PERVs) and Xenotransplantation: Screening for Transmission in Several Clinical Trials and in Experimental Models. Ann Transplant, 2003; 8: 39-48
33. Uygun, BE, Soto-Gutierrez A, Yagi H et al: Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med, 2010; 16: 814-820
34. Sauer IM, Goetz M, Steffen I et al: In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology, 2004; 39: 1408-1414
35. Rozga J, Umehara Y, Trofimenko A et al: A Novel Plasma Filtration Therapy for Hepatic Failure: Preclinical Studies. Ther Apheresis & Dialysis, 2006, 10: 138-144
36. Rozga J: Selective Plasma Filtration Therapy (SEPET™) for Liver Failure - Early Clinical Experience. European Society for Artificial Organs, Krems, Austria, May 2007
37. Davies N, Proven A, Leckie P et al: The Development and Testing of the UCL Liver Support Device (UCL-ARSENEL): Improvement of Survival in Paracetamol-Induced Acute Liver Failure Pigs. Hepatology, 2010; 52(Suppl.): 1092A
38. Sabin S, Merritt JA: Treatment of hepatic coma in cirrhosis by plasmapheresis and plasma infusion (plasma exchange). Ann Int Med., 1968; 68: 1-7
39. De Silvestro G, Marson P, Brandolese R et al: A single institution's experience (1982-1999) with plasma-exchange therapy in patients with fulminant hepatic failure. Int J Artif Organs, 2000; 23: 454-461
40. Kondrup J, Almdal T, Vilstrup H, Tygstrup N: High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs, 1992; 15: 669-676
41. Yoshiba M, Inoue N, Sanjo T et al: Plasmapheresis in acute liver failure. In: Y Nose, PS Malchesky, JW Smith and RS Krakauer, editors. Plasmapheresis Therapeutic Applications and New Techniques. New York: Raven Press, 1983; 399-406
42. Brunner G, Losgen H: Benefits and dangers of plasma exchange in patients with fulminant hepatic failure. In: T Oda, Y Shiokawa, N Inoue (eds.), Therapeutic Plasmapheresis. Cleveland: ISAO Press, 1987; 187-191
43. Munoz SJ, Ballas SK, Moritz MJ et al: Perioperative management of fulminant and subfulminant hepatic failure with therapeutic plasmapheresis. Transplant Proc, 1989; 1: 3535-3536
44. Eguchi S, Kamlot A, Ljubimova J et al: Fulminant Hepatic Failure in Rats: Survival and Effects on Blood Chemistry and Liver Regeneration. Hepatology, 1966; 24: 1452-1459
45. Eguchi S, Lilja MH, Kamlot A et al: Loss and Recovery of Liver Regeneration in Rats with Fulminant Hepatic Failure. J Surg Res, 1997; 72: 112-122
46. Kamohara Y, Sugiyama N, Mizuguchi T et al: Inhibition of signal transducer and activator of transcription factor 3 in rats with acute hepatic failure. Biochem Biophys Res Commun, 2000; 273: 129-135
47. Mizuguchi T, Kamohara Y, Hui T et al: Regulation of c-Met Expression in Rats with Acute Hepatic Failure. J Surg Res, 2001; 99: 385-396
48. Suk KS, Lilja H, Kamohara Y et al: Bioartificial liver treatment in fulminant hepatic failure rats: effect on DNA binding activity of growth induced and liver-enriched transcription factors. J Surg Res, 1999; 85: 243-2450
49. Tsubouchi H, Hirano S, Gohda E et al: Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. Hepatology, 1989; 9: 875-881
50. Roche M, Rondeau P, Singh NR et al: The antioxidant properties of serum albumin. FEBS Lett, 2008; 582: 1783-1787
51. Oettl K, Stauber RE: Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol, 2007; 151: 580-590
52. Anraku M, Yamasaki K, Maruyama T et al: Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res, 2001; 18: 632-639
53. Jalan R, Kerstin S, Mookerjee R et al: Alterations in the functional capacity of albumin in patients with decompensated cirrhosis are associated with increased mortality. Hepatology, 2009; 50: 555-564
54. Lee WC, Uchino S, Fealy N et al: Super high flux hemodialysis at high dialysate flows: an ex vivo assessment. Int J Artif Organs, 2004; 27: 24-28
55. Honoré PM, Zydney AL, Matson JR: High volume and high permeability haemofiltration in sepsis: the evidences and the key issues. Care Crit Ill, 2003; 3: 69-76
56. Morgera S, Haase M, Kuss T et al: Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med., 2006; 34: 2099-104
57. House AA, Ronco C: Extracorporeal blood purification in sepsis and sepsis-related acute kidney injury. Blood Purif, 2008; 26: 30-35
58. Haapanen E, Tiula E: Plasmapheresis with albumin as main substitute in acute hepatic coma. Scand J Gastroenterol, 1972; 7: 75-83
59. Davies N, Proven A, Leckie P et al: The Development and Testing of the UCL Liver Support Device (UCL-ARSENEL): Improvement of Survival in Paracetamol-Induced Acute Liver Failure Pigs. Hepatology, 2010; 52(Suppl.): 1092A
60. Rifai K, Manns MP: Clinical Experience With Prometheus. Ther Apher Dial, 2006; 10: 132-137
61. Dethloff T, Tofteng F, Frederiksen HJ et al: Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: A randomized controlled study. World J Gastroenterol, 2008; 14: 2065-2071
62. Duan Z, Xin A, Zhang S et al: 3-year follow up of acute-on-chronic liver failure (ACLF) subjects in a randomized, controlled, multicenter trial of the ELAD bioartificial liver support system in 49 Chinese subjects reveals significant transplant-free survival (TFS) benefit. Hepatology, 2010; 52(Suppl.): 1089A